Crohns Disease - Pipeline Insight, 2024

This “Crohn’s Disease - Pipeline Insight, 2024, report provides comprehensive insights about 90+ companies and 90+ pipeline drugs in Crohn’s Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Crohn’s Disease Understanding

Crohn’s Disease: Overview

Crohn’s disease is a chronic inflammatory disease of the gastrointestinal tract, where inflammation extends all the way through the intestinal wall from mucosa to serosa. It is a relapsing and remitting disease. Initially only a small segment of the gastrointestinal tract may be involved, but Crohn’s disease has the potential to progress extensively. The inflammation observed in the digestive tract is followed by abdominal pain, severe diarrhea, fatigue, weight loss and malnutrition. Crohn’s disease in people can be both painful and weakening, sometimes leading to life-threatening complications. The inflammation caused in the intestine can be skipped in between the patches of diseased intestine. The signs and symptoms observed in patients suffering from Crohn’s disease tends to vary and can change over a period of time.

Crohn’s Disease - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Crohn’s Disease pipeline landscape is provided which includes the disease overview and Crohn’s Disease treatment guidelines. The assessment part of the report embraces, in depth Crohn’s Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Crohn’s Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Crohn’s Disease R&D. The therapies under development are focused on novel approaches to treat/improve Crohn’s Disease.

Crohn’s Disease Emerging Drugs Chapters

This segment of the Crohn’s Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Crohn’s Disease Emerging Drugs

Guselkumab: Janssen Guselkumab is a human immunoglobulin G1 lambda (IgG1?) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. It is currently in Phase III of clinicaltrial.

RHB-104: Red Hill Biopharma RHB-104 is a potentially groundbreaking, proprietary investigational drug in oral capsule formulation, with potent intracellular, antimycobacterial and anti-inflammatory properties. It is currently in Phase III ofclinicaltrial.

Crohn’s Disease: Therapeutic Assessment

This segment of the report provides insights about the different Crohn’s Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Crohn’s Disease

There are approx. 90+ key companies which are developing the therapies for Crohn’s Disease. The companies which have their Crohn’s Disease drug candidates in the most advanced stage, i.e. Phase III include, Janseen.

Phases

This report covers around 4+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Crohn’s Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Crohn’s Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Crohn’s Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Crohn’s Disease drugs.

Crohn’s Disease Report Insights

• Crohn’s Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Crohn’s Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Crohn’s Disease drugs?
• How many Crohn’s Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Crohn’s Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Crohn’s Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Crohn’s Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Janssen
• Red HillBiopharma
• Amgen
• Pfizer
• Hoffmann-La Roche
• Gilead Sciences
• Eli Lilly and Company
• Celgene
• AstraZeneca
• Abbvie
• Mesoblast
• Alfasigma
• Tiziana Life Sciences
• Abivax
• Arena Pharmaceuticals
• Cytocom
• Amgen
• Priothera
• SLA Pharma
• HAV Vaccines Ltd
• Enzo Biochem Inc.
• VHsquared Ltd.
• Stero Biotechs
• Reistone Biopharma Company Limited
• Qu Biologics
• Provention Bio
• Pfizer
• Mitsubishi Tanabe Pharma Corporation
• Takeda Pharmaceuticals
• Soligenix
• Immunic
• Pfizer
• Atlantic Healthcare
• 4D Pharma
• Landos Biopharma
• Janssen
• Protagonist Therapeutics
• Roche
• Eisai
• Bristol-Myers Squibb
• Iltoo Pharma
• Fast Forward Pharmaceuticals
• Suzhou Connect Biopharmaceuticals
• Theravance Biopharma
• TaiwanJ Pharmaceuticals
• Active Biotech
• Celularity
• Cerecor
• GlaxoSmithKline
• Kang Stem Biotech
• Immunic
• Alpha Cancer Technologies
• Koutif Therapeutics
• Winston Pharmaceuticals
• Tract Therapeutics
• Trio medicines
• Tetherex Pharmaceuticals
• ChemoCentryx
• Algernon Pharmaceuticals
• Neuclone
• Innovimmune Biotherapeutics
• JHL Biotech
• Intract Pharma Ltd
• Innovative Pharmacological Research (IPHAR) Co Ltd
• Innovation Pharmaceuticals
• Exeliom Biosciences SAS
• AbbVie
• Finch Therapeutics
• Akeso Biopharma
• Draconis Pharma
• MakScientific
• Origo Biopharma
• Navidea Biopharmaceuticals
• Orchard Therapeutics
• Xbrane
• Thetis Pharmaceuticals
• Temisis Therapeutics
• Synedgen
• Synlogic
• PlantPraxis
• Morphic Therapeutic
• Metacrine
• Curacle
• Commence Bio Inc
• Cloud Pharmaceuticals
• Chong Kun Dang Pharmaceutical Corp
• Avobis Bio LLC
• Avexegen Therapeutics
• Atlantic Bio Sci
• Assembly Biosciences
• Artelo Biosciences
• Aibios Co Ltd
• Aclaris Therapeutics
• Athos Therapeutics
• Denali Therapeutics
• Educell doo

Key Products

• Guselkumab
• RHB-104
• Infliximab biosimilar
• Etrolizumab
• Filgotinib
• Mirikizumab
• Ozanimod
• Brazikumab
• Risankizumab
• Upadacitinib
• Remestemcel-L
• Rifaximin
• Foralumab
• ABX-464
• Etrasimod
• CYTO-201
• Masitinib
• Mocravimod
• Ortem Topical metronidazole
• HAV anti-MAP vaccine
• Alequel
• V565
• Cannabidiol
• SHR0302
• QBECO-SSI
• PRV-6527
• PF-06651600
• MT-1303
• TAK-018
• SGX203
• IMU 838
• Brepocitinib
• Alicaforsen
• Bacteroides thetaiotaomicron
• BT-11
• JNJ-64304500
• PTG-200
• RG-7880
• E6011
• BMS-986165
• Spesolimab
• Aldesleukin
• FFP104
• CBP-307
• TD-1473
• JKB-122
• Laquinimod
• PDA-001
• MDGN-002
• GSK1070806
• Furestem-CD
• IMU-856
• ACT-101
• KT-1002
• Civamide
• TregCel
• TR8
• SelK2
• CCX507
• NP-178
• NeuLara
• INV-88
• JHL1255
• INT-119
• Anti-inflammatory drug LIS
• Brilacidin
• Faecalibacterium Prausnitzii
• Navitoclax

Research programme: Crohn's disease therapeutics- AK 101

• IBD Program
• MAK 11049
• GI restricted TGF-ß inhibitor

Research programme: mannose receptor-targeted therapeutic agents- Research programme: haematopoietic stem cell based ex vivo gene therapy

• Xcimzane
• TP317
• TEM1657
• SYGN 313
• SYNB 8802
• Adalimumab biosimilar
• MORF 057
• IBD Program
• CU06
• MSC1 & MSC2
• Phospholipid A2 (PLA2)
• CKD-506
• Implantable cell therapies
• Neuregulin-4 (NRG-4)
• ABS11
• ABI-M301
• ART12.11
• AIB-301
• ATI-2138 ITK/TXK/JAK3 Inhibitor
• JAK1/JAK3 Inhibitor
• ITK/TXK/JAK3 Inhibitor
• ATH-001
• ATH-063
• DNL975
• CrohnArt

This product will be delivered within 2 business days.